Interstitial Pneumonia Caused by Cladribine in the Treatment of Classic Hairy Cell Leukemia:a Case Report and Literature Review
1.Department of Hematology,Shaoxing People's Hospital/Shaoxing Hospital,Zhejiang University School of Medicine,Shaoxing 312000,China
2.Clinical Laboratory,Shaoxing People's Hospital/Shaoxing Hospital,Zhejiang University School of Medicine,Shaoxing 312000,China
*Corresponding author: FENG Weiying,Chief physician;E-mail: f-wy@sohu.com
FU Leihua,GE Guoxing,FU Jiaping, et al. Interstitial Pneumonia Caused by Cladribine in the Treatment of Classic Hairy Cell Leukemia:a Case Report and Literature Review [J]. Chinese General Practice, 2020, 23(8): 989-992. DOI: 10.12114/j.issn.1007-9572.2019.00.584.
傅雷华,葛国兴,傅佳萍等. 克拉屈滨治疗经典型毛细胞白血病致间质性肺炎一例报道并文献复习[J]. 中国全科医学, 2020, 23(8): 989-992. DOI: 10.12114/j.issn.1007-9572.2019.00.584.
[1]GREVER M R,LOZANSKI G.Modern strategies for hairy cell leukemia[J].J Clin Oncol,2011,29(5):583-590.DOI:10.1200/JCO.2010.31.7016.
[2]DEARDEN C E,ELSE M,CATOVSKY D.Long-term results for pentostatin and cladribine treatment of hairy cell leukemia[J].Leuk Lymphoma,2011,52(Suppl 2):21-24.DOI:10.3109/10428194.2011.565093.
[3]SAVEN A,BURIAN C,ADUSUMALLI J,et al.Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia[J].Blood,1999,93(8):2471-2477.DOI:10.1006/bcmd.1999.0237.
[4]FALINI B,MARTELLI M P,TIACCI E.BRAF V600E mutation in hairy cell leukemia:from bench to bedside[J].Blood,2016,128(15):1918-1927.DOI:10.1182/blood-2016-07-418434.
[5]BURTHEM J,CAWLEY J C.The bone marrow fibrosis of hairy-cell leukemia is caused by the synthesis and assembly of a fibronectin matrix by the hairy cells[J].Blood,1994,83(2):497-504.DOI:10.1046/j.1537-2995.1994.34294143958.x.
[6]WIERDA W G,BYRD J C,ABRAMSON J S,et al.Hairy cell leukemia,version 2.2018,NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2017,15(11):1414-1427.DOI:10.6004/jnccn.2017.0165.
[7]AHMADZADEH A,SHAHRABI S,JASEB K,et al.BRAF mutation in hairy cell leukemia[J].Oncol Rev,2014,8(2):253.DOI:10.4081/oncol.2014.253.
[8]KREITMAN R J.Hairy cell leukemia:present and future directions[J].Leuk Lymphoma,2019.DOI:10.1080/10428194.2019.1608536.
[9]TROUSSARD X,CORNET E.Hairy cell leukemia 2018:update on diagnosis,risk-stratification,and treatment[J].Am J Hematol,2017,92(12):1382-1390.DOI:10.1002/ajh.24936.
[10]CORNET E,DELMER A,FEUGIER P,et al.Recommendations of the SFH(French society of haematology) for the diagnosis,treatment and follow-up of hairy cell leukaemia[J].Ann Hematol,2014,93(12):1977-1983.DOI:10.1007/s00277-014-2140-y.
[11]ROBAK T,MATUTES E,CATOVSKY D,et al.Hairy cell leukaemia:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2015,26(Suppl 5):v100-107.DOI:10.1093/annonc/mdv200.
[12]SAVOIE L,JOHNSTON J B.Hairy cell leukemia[J].Curr Treat Options Oncol,2001,2(3):217-224.DOI:10.1007/s11864-001-0035-3.
[13]JONES G,PARRY-JONES N,WILKINS B,et al.Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant[J].Br J Haematol,2012,156(2):186-195.DOI:10.1111/j.1365-2141.2011.08931.x.
[14]NAIK R R,SAVEN A.My treatment approach to hairy cell leukemia[J].Mayo Clin Proc,2012,87(1):67-76.DOI:10.1016/j.mayocp.2011.09.001.
[15]GERRIE A S,ZYPCHEN L N,CONNORS J M.Fludarabine and rituximab for relapsed or refractory hairy cell leukemia[J].Blood,2012,119(9):1988-1991.DOI:10.1182/blood-2011-08-371989.
[16]KREITMAN R J,TALLMAN M S,ROBAK T,et al.Phase Ⅰ trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox(CAT-8015 or HA22) in patients with hairy cell leukemia[J].J Clin Oncol,2012,30(15):1822-1828.DOI:10.1200/JCO.2011.38.1756.
[17]DHILLON S.Moxetumomab pasudotox:first global approval[J].Drugs,2018,78(16):1763-1767.DOI:10.1007/s40265-018-1000-9.
[18]DIETRICH S,PIRCHER A,ENDRIS V,et al.BRAF inhibition in hairy cell leukemia with low-dose vemurafenib[J].Blood,2016,127(23):2847-2855.DOI:10.1182/blood-2015-11-680074.
[19]KRAUT E.Infectious complications in hairy cell leukemia[J].Leuk Lymphoma,2011,52(Suppl 2):50-52.DOI:10.3109/10428194.2011.570819.
[20]CAMUS P,KUDOH S,EBINA M.Interstitial lung disease associated with drug therapy[J].Br J Cancer,2004,91(Suppl 2):S18-23.DOI:10.1038/sj.bjc.6602063.
[21]尹文杰,孙录.药物性间质性肺炎[J].中国老年学杂志,2012,32(24):5632-5634.DOI:10.3969/j.issn.1005-9202.2012.24.147.
YIN W J,SUN L.Drug induced interstitial pneumonia[J].Chinese Journal of Gerontology,2012,32(24):5632-5634.DOI:10.3969/j.issn.1005-9202.2012.24.147.
[22]CAMUS P,FANTON A,BONNIAUD P,et al.Interstitial lung disease induced by drugs and radiation[J].Respiration,2004,71(4):301-326.DOI:10.1159/000079633.
[23]MULLER N L,WHITE D A,JIANG H,et al.Diagnosis and management of drug-associated interstitial lung disease[J].Br J Cance,2004,91(Suppl 2):S24-30.DOI:10.1038/sj.bjc.6602064.